Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 711 participants.

Also called NCT04986202

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 711 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04986202
  • EudraCT 2020-005844-47
Other papers using this trial's data
  • Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial Nature medicine, 2026-09 DOI, PubMed 42717033

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Hungary, Japan, Netherlands, Poland, Russia, Slovakia, Sweden, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04986202. Randomized; triple masking; primary purpose treatment. Start 2021-06-30 (actual); primary completion 2024-03-27 (actual). Results posted on 2025-08-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Acronym
ENDEAVOR
Intervention (Drug)
AZD4831
Intervention (Other)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04986202
Content hash
4a38a4fadd8523280ec36fcf20a03550375f4912160953809c418e1f2b443f71